Literature DB >> 26541755

GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.

Bachir Niang1, Liyuan Jin1, Xixi Chen1, Xiaohan Guo1, Hongshuo Zhang1, Qiong Wu2, Arshad Ahmed Padhiar1, Min Xiao3, Deyu Fang4, Jianing Zhang5,6.   

Abstract

GALNT4 belongs to a family of N-acetylgalactosaminyltransferases, which catalyze the transfer of GalNAc to Serine or Threonine residues in the initial step of mucin-type O-linked protein glycosylation. This glycosylation type is the most complex post-translational modification of proteins, playing important roles during cellular differentiation and in pathological disorders. Most of the breast cancer subtypes are estrogen receptor positive, and hence, the estrogen pathway represents a key regulatory network. We investigated the expression of GalNAc-T4 in a panel of mammary epithelial cell lines and found its expression is associated with the estrogen status of the cells. FOXA1, a key transcription factor, functions to promote estrogen responsive gene expression by acting as a cofactor to estrogen receptor alpha (ERα), but all the aspects of this regulatory mechanism are not fully explored. This study found that knockdown of GALNT4 expression in human breast cancer cells attenuated the protein expression of ERα, FOXA1, and Cyclin D1. Further, our immunoprecipitation assays depicted the possibility of FOXA1 to undergo O-GalNAc modifications with a decrease of GalNAc residues in the GALNT4 knockdown cells and also impairment in the FOXA1-ERα association. Rescuing GALNT4 expression could restore the interaction as well as the glycosylation of FOXA1. Together, these findings suggest a key role for GalNAc-T4 in the estrogen pathway through FOXA1 glycosylation.

Entities:  

Keywords:  ERα; FOXA1; GALNT4; O-Glycosylation; Vicia Villosa Lectin (VVL)

Mesh:

Substances:

Year:  2015        PMID: 26541755     DOI: 10.1007/s11010-015-2601-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).

Authors:  E A Williamson; I Wolf; J O'Kelly; S Bose; S Tanosaki; H P Koeffler
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

2.  A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.

Authors:  Jérôme Eeckhoute; Jason S Carroll; Timothy R Geistlinger; Maria I Torres-Arzayus; Myles Brown
Journal:  Genes Dev       Date:  2006-09-15       Impact factor: 11.361

3.  Glycomics hits the big time.

Authors:  Gerald W Hart; Ronald J Copeland
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

4.  Free oligosaccharides to monitor glycoprotein endoplasmic reticulum-associated degradation in Saccharomyces cerevisiae.

Authors:  Hiroto Hirayama; Junichi Seino; Toshihiko Kitajima; Yoshifumi Jigami; Tadashi Suzuki
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

5.  An oestrogen-receptor-alpha-bound human chromatin interactome.

Authors:  Melissa J Fullwood; Mei Hui Liu; You Fu Pan; Jun Liu; Han Xu; Yusoff Bin Mohamed; Yuriy L Orlov; Stoyan Velkov; Andrea Ho; Poh Huay Mei; Elaine G Y Chew; Phillips Yao Hui Huang; Willem-Jan Welboren; Yuyuan Han; Hong Sain Ooi; Pramila N Ariyaratne; Vinsensius B Vega; Yanquan Luo; Peck Yean Tan; Pei Ye Choy; K D Senali Abayratna Wansa; Bing Zhao; Kar Sian Lim; Shi Chi Leow; Jit Sin Yow; Roy Joseph; Haixia Li; Kartiki V Desai; Jane S Thomsen; Yew Kok Lee; R Krishna Murthy Karuturi; Thoreau Herve; Guillaume Bourque; Hendrik G Stunnenberg; Xiaoan Ruan; Valere Cacheux-Rataboul; Wing-Kin Sung; Edison T Liu; Chia-Lin Wei; Edwin Cheung; Yijun Ruan
Journal:  Nature       Date:  2009-11-05       Impact factor: 49.962

6.  N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.

Authors:  Chen Wu; Xiaodan Guo; Weina Wang; Yun Wang; Yaojun Shan; Bo Zhang; Wenqian Song; Sisi Ma; Jianfeng Ge; Hao Deng; Mingsheng Zhu
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

7.  Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat.

Authors:  E P Bennett; H Hassan; U Mandel; E Mirgorodskaya; P Roepstorff; J Burchell; J Taylor-Papadimitriou; M A Hollingsworth; G Merkx; A G van Kessel; H Eiberg; R Steffensen; H Clausen
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.

Authors:  C Gong; K Fujino; L J Monteiro; A R Gomes; R Drost; H Davidson-Smith; S Takeda; U S Khoo; J Jonkers; D Sproul; E W-F Lam
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

Review 9.  Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development.

Authors:  Bramanandam Manavathi; Venkata S K Samanthapudi; Vijay Narasimha Reddy Gajulapalli
Journal:  Front Cell Dev Biol       Date:  2014-08-12

10.  Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.

Authors:  Caroline B Madsen; Cecilie Petersen; Kirstine Lavrsen; Mikkel Harndahl; Søren Buus; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more
  5 in total

1.  Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies.

Authors:  Yasuyuki Matsumoto; Matthew R Kudelka; Melinda S Hanes; Sylvain Lehoux; Sucharita Dutta; Mark B Jones; Kathryn A Stackhouse; Gabrielle E Cervoni; Jamie Heimburg-Molinaro; David F Smith; Tongzhong Ju; Elliot L Chaikof; Richard D Cummings
Journal:  Glycobiology       Date:  2020-04-20       Impact factor: 4.313

2.  Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation.

Authors:  Earnest James Paul Daniel; Matilde Las Rivas; Erandi Lira-Navarrete; Ana García-García; Ramon Hurtado-Guerrero; Henrik Clausen; Thomas A Gerken
Journal:  Glycobiology       Date:  2020-10-21       Impact factor: 4.313

Review 3.  Mucins as anti-cancer targets: perspectives of the glycobiologist.

Authors:  Inka Brockhausen; Jacob Melamed
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

4.  miR‑4262 inhibits colon cancer cell proliferation via targeting of GALNT4.

Authors:  Jian-Jun Qu; Xiang-Yang Qu; De-Zhen Zhou
Journal:  Mol Med Rep       Date:  2017-07-21       Impact factor: 2.952

Review 5.  Unconventional protein post-translational modifications: the helmsmen in breast cancer.

Authors:  Jiena Liu; Qin Wang; Yujuan Kang; Shouping Xu; Da Pang
Journal:  Cell Biosci       Date:  2022-02-25       Impact factor: 7.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.